文献速递血液净化与透析肾血管病与高血压水电解质与酸碱

维持性血透中降低透析液钠浓度的随机临床试验

Dialysate Sodium Lowering in Maintenance Hemodialysis: A Randomized Clinical Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-02-13

本研究将42名维持性血透患者按2:1随机分配至透析液钠135 vs 138 mEq/L治疗6个月,随后低钠组在12周延伸期升至140 mEq/L。结果显示135 vs 138 mEq/L对透析中低血压变化率无差异,但低钠组症状更重;135 vs 138 mEq/L仅小幅减少透析间期体重增长,对透析前血压无影响;从135升至140 mEq/L可减少透析中低血压并显著升高血压。

要点

  • 透析液钠135 vs 138 mEq/L对透析中低血压变化率无差异,但低钠组症状更重。
  • 135 vs 138 mEq/L小幅减少透析间期体重增长,对透析前血压无影响。
  • 从135升至140 mEq/L可减少透析中低血压,但小幅增加透析间期体重增长并显著升高透析前血压。

核心结论

  • 透析液钠135 vs 138 mEq/L仅小幅减少透析间期体重增长,对透析中低血压或透析前血压无影响,但症状增加。
  • 从135升至140 mEq/L可减少透析中低血压,小幅增加透析间期体重增长并显著升高透析前血压。

研究设计与样本

  • 随机对照试验,42名维持性血透患者按2:1随机分配至透析液钠135 vs 138 mEq/L治疗6个月。
  • 随后12周延伸期,低钠组(135 mEq/L)透析液钠升至140 mEq/L。
  • 主要结局为透析中低血压(IDH),次要结局包括透析失衡症状、急诊就诊/住院、透析间期体重增长和血压。
  • 采用线性混合回归分析组间纵向变化。

主要发现

  • 135 vs 138 mEq/L组IDH变化率(每100次治疗每月事件数)平均变化分别为2.8(95%CI 0.8–9.5) vs 2.7(95%CI 1.1–6.2),斜率比0.96(95%CI 0.26–3.61)。
  • 135 vs 138 mEq/L组急诊就诊/住院(每100患者月事件数)分别为7.3(95%CI 2.3–12.4) vs 6.7(95%CI 2.9–10.6),差值0.6(95%CI −6.9–5.8)。
  • 135 mEq/L组症状评分无变化(0.7,95%CI −1.4–2.7),138 mEq/L组症状评分下降(95%CI 5.0–8.5至2.0),差值6.0(95%CI 2.1–9.8)。
  • 135 mEq/L组透析间期体重增长下降,138 mEq/L组无变化(−0.3 [95%CI −0.5–0.0] vs 0.3 [95%CI 0.0–0.6] kg/6个月),差值−0.6(95%CI −0.1至−1.0)kg。
  • 延伸期从135升至140 mEq/L,透析间期体重增长增加0.2(95%CI 0.1–0.3)kg,透析前血压升高7.0(95%CI 4.8–9.2)/3.9(95%CI 2.6–5.1)mm Hg,IDH减少(OR 0.66,95%CI 0.45–0.97)。

临床怎么用

  • 对维持性血透患者,透析液钠135 vs 138 mEq/L对IDH无差异但症状更多,选择时需权衡症状负担。
  • 从135升至140 mEq/L可减少IDH,但需监测透析间期体重增长和透析前血压升高。

局限性

  • 样本量较小(42例),可能限制统计效能和结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Treatment to dialysate sodium 135 versus 138 mEq/L led to no difference in the rate of change in intradialytic hypotension, but symptoms were greater in the low arm. Use of a dialysate sodium concentration of 135 versus 138 mEq/L led to a small reduction in interdialytic weight gain, but had no effect on predialysis BP. Raising dialysate sodium concentration from 135 to 140 mEq/L reduced intradialytic hypotension and was associated with a marked increase in BP. BACKGROUND: Lowering dialysate sodium concentration may improve volume and BP control in patients on maintenance hemodialysis. METHODS: We randomized 42 participants 2:1 to dialysate sodium 135 versus 138 mEq/L for 6 months. This was followed by a 12-week extension phase in which sodium was increased to 140 mEq/L in low-arm participants. The primary outcome was intradialytic hypotension (IDH). Secondary outcomes included dialysis disequilibrium symptoms, emergency room visits/hospitalizations, interdialytic weight gain, and BP. Longitudinal changes across arms were analyzed using linear mixed regression. RESULTS: Treatment to dialysate sodium 135 versus 138 mEq/L was not associated with a difference in a change in the rate of IDH (mean change [95% confidence interval], 2.8 [0.8 to 9.5] versus 2.7 [1.1 to 6.2] events per 100 treatments per month); ratio of slopes 0.96 (0.26 to 3.61) or emergency room visits/hospitalizations (7.3 [2.3 to 12.4] versus 6.7 [2.9 to 10.6] events per 100 patient-months); difference 0.6 (−6.9 to 5.8). Symptom score was unchanged in the 135 mEq/L arm (0.7 [−1.4 to 2.7]) and decreased in the 138 mEq/L arm ([5.0 to 8.5 to 2.0]; difference 6.0 [2.1 to 9.8]). Interdialytic weight gain declined in the 135 mEq/L arm and was unchanged in the 138 mEq/L arm (−0.3 [−0.5 to 0.0] versus 0.3 [0.0 to 0.6] kg over 6 months; difference [−0.6 (−0.1 to −1.0)] kg). In the extension phase, raising dialysate sodium concentration from 135 to 140 mEq/L was associated with an increase in interdialytic weight gain (0.2 [0.1 to 0.3] kg) and predialysis BP (7.0 [4.8 to 9.2]/3.9 [2.6 to 5.1] mm Hg) and a reduction in IDH (odds ratio, 0.66 [0.45 to 0.97]). CONCLUSIONS: Use of a dialysate sodium concentration of 135 as compared with 138 mEq/L was associated with a small reduction in interdialytic weight gain without affecting IDH or predialysis BP, but with an increase in symptoms. Raising dialysate sodium concentration from 135 to 140 mEq/L was associated with a reduction in IDH, small increase in interdialytic weight gain, and marked increase in predialysis BP. CLINICAL TRIAL REGISTRATION NUMBER: NCT03144817.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Miskulin DC, Tighiouart H, Hsu CM, et al. Dialysate Sodium Lowering in Maintenance Hemodialysis: A Randomized Clinical Trial. Clin J Am Soc Nephrol. 2024. PMID: 38349776. doi:10.2215/CJN.0000000000000431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。